Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide
Paola Papaldo(Cancer Institute (WIA)), Paolo Marolla(Catholic University of America), Carlo Barone(Università Cattolica del Sacro Cuore), Claudio Botti(Catholic University of America), Paolo Carlini(National Cancer Institute), E. Terzoli(Catholic University of America), Cecilia Nisticò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Alessandra Fabi(Agostino Gemelli University Polyclinic), Carlo Vitucci(Molecular Oncology (United States)), Eugenio Cammilluzzi(Molecular Oncology (United States)), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Giuseppe Lepidini(Molecular Oncology (United States)), Mauro Antimi(Catholic University of America), Diana Giannarelli(Agostino Gemelli University Polyclinic), Enrico Cortesi(Sapienza University of Rome), Luigi Di Lauro, Francesca Conti(Catholic University of America), Serena Di Cosimo(Fondazione IRCCS Istituto Nazionale dei Tumori), Massimo Lopez(Catholic University of America), Patrizia Vici(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 76
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan
|JAMA Oncology|2018|418